Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Ohio State University Comprehensive Cancer Center
Sponsor:
Collaborator:
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Manisha Shah, Ohio State University Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01723202
First received: October 22, 2012
Last updated: August 25, 2014
Last verified: August 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)